Advanced search
Publication Cover
Autoimmunity Volume 52, 2019 - Issue 3
Submit an article Journal homepage
189
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Effects of intermittent T-cell cluster disaggregation on proliferative capacity and checkpoint marker expression

Matthew LiDepartment of Surgery, Center for Surgery, Innovation, and Bioengineering, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, MA, USA; View further author information
,
Ling-Yee ChinDepartment of Surgery, Center for Surgery, Innovation, and Bioengineering, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, MA, USA; View further author information
,
Sykuri ShukorDepartment of Surgery, Center for Surgery, Innovation, and Bioengineering, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, MA, USA; View further author information
,
Alfred G. TamayoDepartment of Surgery, Center for Surgery, Innovation, and Bioengineering, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, MA, USA; View further author information
,
Marcela V. MausCancer Center, Massachusetts General Hospital, Boston, MA, USA; ;Harvard Medical School, Boston, MA, USA; View further author information
&
Biju ParekkadanDepartment of Surgery, Center for Surgery, Innovation, and Bioengineering, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, MA, USA; ;Harvard Stem Cell Institute, Cambridge, MA, USA; ;Department of Biomedical Engineering, Rutgers University, Piscataway, NJ, USACorrespondence[email protected]
View further author information
Pages 102-107 | Received 15 Feb 2019, Accepted 06 Jun 2019, Published online: 25 Jun 2019

References

  • Parker LL, Do MT, Westwood JA, et al. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther. 2000;11:2377–2387.
  • Rasmusson I, Ringdén O, Sundberg B, et al. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res. 2005;305:33–41.
  • Smith C, Økern G, Rehan S, et al. Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS immune cell serum replacement. Clin Trans Immunol. 2015;4:e31.
  • General Electric. Xuri (TM) cell expansion system W25 user manual. https://cdn.gelifesciences.com/dmm3bwsv3/AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=17036.
  • Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486–499.
  • Yang X, Jiang X, Chen G, et al. T cell Ig mucin-3 promotes homeostasis of sepsis by negatively regulating the TLR response. J Immunol. 2013;190:2068–2079.
  • Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492–499.
  • Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187–2194.
  • Iwai Y, Hamanishi J, Chamoto K, et al. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24:26.
  • Lee J, Ahn E, Kissick HT, et al. Reinvigorating exhausted T cells by blockade of the PD-1 pathway. For Immunopathol Dis Ther. 2015;6:7–17.
  • Jiang Y, Li Y, Zhu BT. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6:e1792.
  • Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA. 2010;107:7875–7880.
  • Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest. 2007;117:3383–3392.
  • Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917–927.
  • Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell checkpoint by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10:29–37.
  • Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cell IFN- -mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71:3540–3551.
  • Zhou Q, Munger ME, Veenstra RG, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell checkpoint phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117:4501–4510.
  • TIGIT promotes tumor immune escape via CD8+ T-cell checkpoint. Cancer Discov. 2015;5:1–11.
  • Chew GM, Fujita T, Webb GM, et al. TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection. PLoS Pathog. 2016;12:e1005349.
  • Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989–1004.
  • McKee C, Chaudhry GR. Advances and challenges in stem cell culture. Colloids Surf B Biointerfaces. 2017;159:62–77.
  • Fennema E, Rivron N, Rouwkema J, et al. Spheroid culture as a tool for creating 3D complex tissues. Trends Biotechnol. 2013;31:108–115.
  • Abecasis B, Aguiar T, Arnault É, et al. Expansion of 3D human induced pluripotent stem cell aggregates in bioreactors: bioprocess intensification and scaling-up approaches. J Biotechnol. 2017;246:81–93.
  • Wu J, Rostami MR, Cadavid Olaya DP, et al. Oxygen transport and stem cell aggregation in stirred-suspension bioreactor cultures. PLoS One. 2014;9:e102486.
  • Carlsson J, Acker H. Relations between pH, oxygen partial pressure and growth in cultured cell spheroids. Int J Cancer. 1988;42:715–720.
  • Lin R-Z, Lin RZ, Chang HY. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol J. 2008;3:1172–1184.
  • Mueller-Klieser W. Three-dimensional cell cultures: from molecular mechanisms to clinical applications. Am J Physiol Cell Physiol. 1997;273:C1109–C1123.
  • Yoon D, Osborn M, Tolar J, et al. Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-In CAR-T. Int J Mol Sci. 2018;19:340.
  • Gay F, D’Agostino M, Giaccone L, et al. Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors. Clin Lymphoma Myeloma Leuk. 2017;17:471–478.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.